Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.

CEO

Sébastien Plouffe

Employees

1300

Country

Canada

ISIN

CA24463V1013

WKN

000A3CN14

Listings

0 Comments

Share your thoughts

FAQ

What is Defence Therapeutics stock price today?▼

The current price of DTCFF is $0.36 USD — it has decreased by -6.2% in the past 24 hours. Watch Defence Therapeutics stock price performance more closely on the chart.

What is Defence Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Defence Therapeutics stocks are traded under the ticker DTCFF.

Is Defence Therapeutics stock price growing?▼

DTCFF stock has fallen by -2.75% compared to the previous week, the month change is a +21.41% rise, over the last year Defence Therapeutics has showed a -34.39% decrease.

What is Defence Therapeutics market cap?▼

Today Defence Therapeutics has the market capitalization of 27.31M

What were Defence Therapeutics earnings last quarter?▼

DTCFF earnings for the last quarter are -0.04 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Defence Therapeutics revenue for the last year?▼

Defence Therapeutics revenue for the last year amounts to 0 USD.

What is Defence Therapeutics net income for the last year?▼

DTCFF net income for the last year is -2.52M USD.

How many employees does Defence Therapeutics have?▼

As of September 04, 2026, the company has 1,300 employees.

In which sector is Defence Therapeutics located?▼

Defence Therapeutics operates in the Health & Wellness sector.

When did Defence Therapeutics complete a stock split?▼

Defence Therapeutics has not had any recent stock splits.

Where is Defence Therapeutics headquartered?▼

Defence Therapeutics is headquartered in Vancouver, Canada.